TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1527296
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous deslanoside (0.002 mg/kg body weight)
Study: 1527296
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg of deslanoside (open label assessment)
Study: 1527296
Drug: Deslanoside (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deslanoside (both doses)
Study: 7720153
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no medication)
Study: 29352518
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion (CWI) of 0.2% ropivacaine at 10 ml/h for 48 hours
Study: 24251363
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing of warfarin
Study: 24251361
Drug: Clinically guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically guided dosing of warfarin
Study: 16778691
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural steroid injections at C7-T1
Study: 11434595
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once daily, amoxycillin 750 mg three times a day, metronidazole 500 mg three times a day (RAM)
Study: 3286439
Drug: Exifone 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exifone 600 mg/d
Study: 3286439
Drug: Exifone 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exifone 1200 mg/d
Study: 29561282
Drug: Postoperative 5-fluorouracil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative 5-fluorouracil-based adjuvant therapies
Study: 8942248
Drug: Chloral 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral 40 mg/kg
Study: 2240505
Drug: Trimeprazine 3
Normalized name: trimeprazine 30 MG per 5 ML Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine 3 mg/kg
Study: 2936269
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg/kg
Study: 7138721
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position for 2.5 min or more during and after injection of 3 ml of 0.5% isobaric bupivacaine‐HCl
Study: 30718952
Drug: Indacaterol/glycopyrronium (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg once daily for 16 weeks
Study: 18808404
Drug: Standard-of-care immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care immunosuppression (Thymoglobulin and/or pulse steroids)
Study: 17134488
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose intravenous furosemide 40 mg (Group 1)
Study: 17134488
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous furosemide 120 mg (Group 2)
Study: 12945021
Drug: Topical amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amitriptyline 50 mmol/L
Study: 12945021
Drug: Topical amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amitriptyline 100 mmol/L
Study: 12945021
Drug: Topical amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amitriptyline 10 mmol/L
Study: 12945021
Drug: Topical amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amitriptyline
Study: 2064495
Drug: Niacin 2000
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 2000 mg
Study: 20855072
Drug: Niacin 1500
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin 1500 mg
Study: 2064495
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and diet treatment
Study: 24827136
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C without maintenance chemotherapy (MMC/No-maint)
Study: 24827136
Drug: Cisplatin without
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin without maintenance chemotherapy (CisP/No-maint)
Study: 15877562
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (oxybutynin IR titrated from 2.5 mg per day to 5.0 mg three times a day)
Study: 10499828
Drug: Na2 ethylenediaminetetraacetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2 ethylenediaminetetraacetic acid (edta) solution
Study: 1643676
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg.kg‐1
Study: 1659494
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 to 40 mg QD)
Study: 1659494
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil (120 to 480 mg QD)
Study: 10657866
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone
Study: 11112678
Drug: Oral cefixime
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefixime
Study: 29503075
Drug: Intravenous levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous levofloxacin
Study: 27034958
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA supplementation at 3 g/d for 8 weeks
Study: 25144625
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of 50-60 min of aerobic exercise
Study: 1948517
Drug: Ceftriaxone 250
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 250 mg IM
Study: 15683433
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg b.i.d.
Study: 2892255
Drug: Nizatidine 25
Normalized name: nizatidine 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 25 mg b.i.d.
Study: 20078514
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium suppository
Study: 25260983
Drug: Acetaminophen suppository
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen suppository
Study: 25260983
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no analgesic)
Study: 21797795
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of angiotensin II receptor antagonist (ARB) and controlled-release nifedipine (20-40 mg)
Study: 16999056
Drug: Pharmacokinetically enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) twice daily
Study: 10691221
Drug: BFCN (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFCN (bupivacaine 2.5 mg, fentanyl 25 microg, clonidine 30 microg, neostigmine 10 microg)
Study: 1858176
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen
Study: 18564231
Drug: fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine 4 mg
Study: 28285751
Drug: Oxandrolone (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.06 mg/kg daily)
Study: 21748366
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) only at 5 or 10 g/day
Study: 21748366
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) + recombinant human growth hormone (rhGH) at 0, 3.0 or 5.0 μg/kg/day
Study: 18978489
Drug: Galantamine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (24 mg/d)
Study: 9613540
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL 0.125% bupivacaine (n = 18)
Study: 9613540
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL 0.25% bupivacaine (n = 20)
Study: 9613540
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL saline (Control; n = 21)
Study: 7627864
Drug: Non-drainage during
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drainage during saline infusion
Study: 7627864
Drug: Non-drainage during
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drainage during mannitol infusion
Study: 6111295
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no clemastine treatment)
Study: 24220376
Drug: Merocel nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merocel nasal tampon within glove finger moistened with tetracaine 0.25% solution, removed after 48 hours
Study: 28483774
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (IV tPA) alone
Study: 25777831
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (IV tPA) + Solitaire revascularization device
Study: 23740224
Drug: Combined endpoint
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endpoint (Dabigatran + Warfarin)
Study: 9187886
Drug: Aflurax 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflurax 1200 mg, two tablets four times daily
Study: 24651151
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection of the Rectus Femoris (RF) muscle
Study: 17998023
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg taken twice a day for 7 days)
Study: 15824911
Drug: Ciclesonide via
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide via hydrofluoroalkane metered-dose inhaler
Study: 15824911
Drug: Budesonide via
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide via chlorofluorocarbon metered-dose inhaler
Study: 2501104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and sodium cromoglycate
Study: 26516142
Drug: Adjuvanted and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted and unadjuvanted vaccine groups
Study: 24810369
Drug: elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elosulfase alfa 2.0 mg/kg/week
Study: 24810369
Drug: elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elosulfase alfa 2.0 mg/kg/every other week (qow)
Study: 23573238
Drug: Reduced glycerin
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced glycerin formulation of tenofovir 1% gel
Study: 30148449
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 µ/mL
Study: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) 3 mg
Study: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) 9 mg
Study: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) 18 mg
Study: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) 36 mg
Study: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) with high-fat breakfast (9 mg)
Study: 14517193
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) with high-fat breakfast (36 mg)
Study: 10863679
Drug: Cognitive-behavioral skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral skills training (CBST) treatment
Study: 10863679
Drug: Combined (biofeedback/CBST)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined (biofeedback/CBST) treatment
Study: 290726
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg)
Study: 3515927
Drug: Codeine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (60 or 120 mg)
Study: 23551622
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once a day (OaD)
Study: 22429760
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg as needed (PRN)
Study: 16793612
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine blood transfusion and fluid infusion)
Study: 10669060
Drug: Progressive increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive increase in magnitude of reinforcement for abstinence with a reset contingency for drug use
Study: 22246026
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg subcutaneous)
Study: 1587064
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg racemic mephenytoin alone
Study: 21641663
Drug: Anticonvulsants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsants and benzodiazepines
Study: 9640079
Drug: IHD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IHD with HLP without aspirin
Study: 2868207
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone in addition to high-dose oral prednisolone and standard bronchodilator therapy
Study: 2868207
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral prednisolone and standard bronchodilator therapy
Study: 24582042
Drug: Iodixanol-320 at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol-320 at 5.0 mL/sec flow rate (group 3)
Study: 24582042
Drug: Iodixanol-320 at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol-320 at 6.2 mL/sec flow rate (group 2)
Study: 24582042
Drug: Iomeprol-400 at
Normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol-400 at 5.0 mL/sec flow rate (group 1)
Study: 22483976
Drug: Intralipid 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 40 mL/h
Study: 31679431
Drug: Liuweibuqi (LWBQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuweibuqi (LWBQ) capsules (low dose: 1 LWBQ capsule + 8 starch capsules; medium dose: 3 LWBQ capsules + 6 starch capsules; high dose: 9 LWBQ capsules) for 30 days, 3 times a day
Study: 31679431
Drug: Starch capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch capsules (control group)
Study: 15200747
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT)
Study: 9243353
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg)
Study: 19129751
Drug: EVT 301
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVT 301 (75 mg) in AD subjects
Study: 17389559
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch
Study: 17957909
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (ethinyl estradiol 30 microg and levonorgestrel 150 microg)
Study: 7539854
Drug: Doxazosin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (all doses)
Study: 2278720
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metoclopramide (M)
Study: 23837939
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide pulse therapy (CPT)
Study: 30298667
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral prednisolone
Study: 21383283
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (BV)
Study: 12939564
Drug: lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 10 mg
Study: 15543081
Drug: lercanidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 20 mg
Study: 10517716
Drug: Raloxifene (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (combined 60 mg/d and 120 mg/d)
Study: 8529160
Drug: 1% idoxuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% idoxuridine ointment
Study: 8529160
Drug: 2% trifluorothymidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% trifluorothymidine ointment
Study: 28705190
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (80 mg once daily)
Study: 9532989
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin
Study: 23432755
Drug: high-level tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high-level tacrolimus (TAC, 8-12 μg/L) and low-level sirolimus (SIR, 3-7 μg/L) (TACH/SIRL, n=149)
Study: 21029339
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg
Study: 11789591
Drug: SKI 306X
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SKI 306X 200 mg t.i.d.
Study: 11789591
Drug: SKI 306X
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SKI 306X 400 mg t.i.d.
Study: 11789591
Drug: SKI 306X
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SKI 306X 600 mg t.i.d.
Study: 9677830
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (IgG and IgM) measured at 6 months
Study: 30064403
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) only
Study: 30064403
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (CO‐OP) + splint
Study: 27296249
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special treatment preparation (control group, n=394).
Study: 23687231
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in lactated Ringer's solution (group D)
Study: 18492837
Drug: CHO+PRO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO+PRO treatment
Study: 16793810
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg controlled and extended release)
Study: 3009077
Drug: Beet-fibre meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beet-fibre meal (10.8 g dietary fibre from sugar beet)
Study: 20139427
Drug: Oral levonorgestrel
Normalized name: levonorgestrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levonorgestrel (0.75 mg x 4, at 24 h intervals on LH + 1 to LH + 4; n = 8)
Study: 18248661
Drug: Intraduodenal PHA
Normalized name: PHA-767491
DrugBank: PHA-767491 (DB17043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal PHA (150 microg, 1.5 mg, 15 mg)
Study: 18248661
Drug: CCK(1) receptor
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK(1) receptor antagonist dexloxiglumide
Study: 15215806
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.5)
Study: 14978854
Drug: Ximelagatran (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (36 mg twice daily)
Study: 7844607
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy with cisplatin 60 mg/m2 and epirubicin 110 mg/m2 administered at 3-week intervals for three cycles, followed by pelvic radiotherapy.
Study: 7844607
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (chemotherapy followed by radiotherapy).
Study: 2333832
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral caffeine
Study: 9846599
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral caffeine
Study: 2333832
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral caffeine
Study: 313353
Drug: Intravenous vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vasopressin (IVV) started at 0.3 U/min, increased to 1.5 U/min as needed
Study: 23032746
Drug: Vismodegib (GDC‐0449;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (GDC‐0449; 150 mg daily)
Study: 17166775
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) adjunctive treatment
Study: 10930900
Drug: Omeprazole MUPS
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole MUPS 20 mg